Bajaj Healthcare Ltd

Bajaj Healthcare Ltd has executed a Deed of Assignment for the sale of its undertaking located at Plot No. D-2/CH/42 & D-2/CH/43, Dahej Industrial Area, GIDC, Bharuch, Gujarat, to Spa Vet Private Limited and Indosol Pure Technologies Private Limited. The transaction, valued at approximately ₹14.67 Crores, does not involve related parties. The undertaking was not operational in the last financial year, contributing nil turnover. The company has complied with SEBI Listing Regulations, including obtaining shareholder approval for the slump sale. The trading window for designated persons remains closed.

Bajaj Healthcare Ltd has announced a Board of Directors meeting scheduled for October 17, 2026. The primary agenda is to consider and approve the un-audited financial results for the quarter and half-year ended September 30, 2026. Concurrently, the company has informed that the trading window for its securities will remain closed for all insiders and designated persons from October 1, 2026, until 48 hours after the declaration of these financial results, in compliance with SEBI regulations.

Bajaj Healthcare Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in effect from October 1, 2026, and will continue until 48 hours after the declaration of the company's un-audited financial results for the quarter and half-year ended September 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading during the period leading up to and immediately following the financial results announcement.

Bajaj Healthcare Ltd has announced that Monday, September 14, 2026, has been fixed as the Record Date for determining shareholder entitlement to the Final Dividend for the financial year 2025-26. The proposed dividend is 30%, equivalent to ₹1.50 per equity share. This dividend is subject to declaration and approval by the shareholders at the upcoming Annual General Meeting. Shareholders registered on the company's books or beneficial owners as per depository records on the Record Date will receive the dividend, if approved.

Bajaj Healthcare Ltd has informed the stock exchanges about the dispatch of inland letters to shareholders who have not registered their email addresses. These letters provide a web-link to access the Annual Report for the Financial Year 2025-26. The company is also reminding shareholders to update their KYC details and dematerialize physical securities as per SEBI regulations. The 33rd Annual General Meeting is scheduled for September 21, 2026, via Video Conferencing.

Bajaj Healthcare Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as required by SEBI regulations. The report, which is an integral part of the Annual Report, details the company's corporate identity, business activities, operations, and employee data on a standalone basis. The company's primary business activity is the manufacture and sale of pharmaceutical products, contributing 100% of its turnover. Exports accounted for approximately 31% of the total turnover. The report also provides details on the company's locations, markets served, and employee statistics, including a breakdown of permanent and other than permanent employees and workers.

Bajaj Healthcare Limited has announced its 33rd Annual General Meeting (AGM) scheduled for Monday, September 21, 2026, at 3:00 p.m. IST, to be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company has dispatched the Annual Report for FY 2025-26 and the AGM notice to shareholders. The report details the company's financial and non-financial performance, highlighting its evolution from API business to specialized molecules and formulations. Shareholders can participate in e-voting from September 17 to September 20, 2026. The AGM will cover the company's strategic progress and future outlook.

Bajaj Healthcare Limited has announced its 33rd Annual General Meeting (AGM) will be held on Monday, September 21, 2026, at 3:00 p.m. IST, exclusively through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company has also dispatched the Annual Report for the financial year 2025-26 to its shareholders. The report details the company's performance, strategic evolution from API business to formulations, and future plans. Shareholders can access the Annual Report online and participate in e-voting from September 17 to September 20, 2026. The cut-off date for e-voting eligibility is September 14, 2026.

Bajaj Healthcare Limited has received approval from the Drug Controller General of India (DCGI) to manufacture and market Cenobamate API and Cenobamate Tablets in various strengths (12.5 mg to 200 mg). This makes Bajaj Healthcare the first company to launch Cenobamate in India. The approval follows a recommendation from the Subject Expert Committee (SEC) and strengthens the company's presence in the Central Nervous System (CNS) segment. Cenobamate is an antiseizure medication for partial-onset seizures in adults. The company highlights its integrated API and formulation capabilities and aims to make this advanced therapy available to patients in India, expecting it to drive long-term growth.

Bajaj Healthcare Ltd announced the grant of 275 employee stock options under its 2024 ESOP plan. The options have an exercise price of ₹5 each and are convertible into equity shares. The Nomination & Remuneration Committee approved the grant on July 20, 2026. The options vest over a period of up to 4 years, with a minimum one-year period between grant and vesting. Vested options can be exercised within 5 years of vesting. The shares arising from exercised options will not be subject to a lock-in period, though insider trading regulations may apply.